Biotech Values

[DewDiligence]

FoB collaboration between two companies I’d never heard of:

http://www.marketwatch.com/story/catalent-and-umn-pharma-announce-collaboration-for-biosimilar-development-and-production-in-japan-2012-12-13

Catalent Pharma Solutions and UMN Pharma Inc. today announced the signing of an agreement to provide UMN Pharma a broad range of biosimilar cell lines using Catalent's proprietary GPEx(R) technology. The development and manufacturing programs will benefit from the GPEx technology producing very stable and high yielding cell lines. [Does any company ever talk about having *low*-yielding cell lines?]

Under the agreement, UMN Pharma and its subsidiary UNIGEN, which is a contract manufacturer, will produce a number of biosimilars using Catalent's GPEx cell lines. UMN Pharma, separately, will build an alliance of pharmaceutical companies for product development including clinical trials, marketing and sales. UMN Pharma plans to begin multiple biosimilar projects with their alliance companies for the Asian market on an ongoing basis.